The objective was to analyze and discuss the implications of a nonmalignant CD30+ late seroma. Methods included collection of seroma fluid and peripheral blood from a patient with a late seroma 22 years after initial breast reconstruction. A panel of 24 monoclonal antibodies was used to detect T-cell receptor Vβ regions present on ~70% of normal human peripheral blood T lymphocytes. Flow cytometry gated on CD3+ and CD30+ activated T lymphocytes. Cytospins were used to inspect the morphology of the T lymphocytes. Results from the seroma fluid cytology revealed a spectrum of activated T lymphocytes as seen in the blood of patients with immune disorders such as infectious mononucleosis. Cells were judged to be nonmalignant by routine pathology. Flow cytometry revealed >23% of CD3+ T lymphocytes belonged to an expanded T-cell family expressing TCRVβ13.2. Most Vβ13.2 cells expressed T-cell activation antigen CD30 indicating that CD30 is not restricted to anaplastic large cell lymphoma (ALCL) in seroma fluids. A smaller expanded population of CD30+ T lymphocytes expressing TCRVβ 13.2 was detected in the blood. In conclusion, in this index case, an expanded population of CD30+ activated T lymphocytes was detected in seroma fluid surrounding a textured breast implant as well as in peripheral blood, consistent with a local and systemic immune response. The demonstration of an expanded CD30+ T-cell population in a polyclonal background suggests a possible role for bacterial superantigens as a pathogenic factor. These data further suggest that breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) may be the end stage of a CD30+ T-cell lymphoproliferative disorder.
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The development and progression of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) remains inadequately understood. There are now more than 200 women worldwide who have been diagnosed with BIA-ALCL. 1 The single most common presentation of BIA-ALCL is an accumulation of fluid (periprosthetic fluid/late seroma) occurring on average 9 to 10 years following implantation. 1 The association of anaplastic lymphoma kinase (ALK)-negative ALCL arising within this fluid and the surrounding capsule has led to the description of a distinct malignancy. BIA-ALCL is CD30+, ALK-, and usually CD4+. Clonal T-cell receptor gene rearrangements have been detected in clinical specimens and cell lines derived from BIA-ALCL. 1, 2 High expression of JUNB (a transcription factor for which there is no known abbreviation), suppressor of cytokine signaling 3, and special AT-rich sequencing-binding protein-1 have been reported as potential biomarkers of malignant cells in BIA-ALCL, similar to cutaneous ALCL. 3 In addition, recent studies have revealed a linear relationship between the number of bacteria/biofilm on the implant surface and the amount of T lymphocytic infiltrate on textured implants associated with BIA-ALCL. 4 
CASE HISTORY
The patient is a 69-year-old woman who presented in October 2015 with a late periprosthetic fluid collection (seroma) 5 22 years after initial breast reconstruction (Figure 1) . She was first diagnosed in 1993 with multifocal intraductal breast cancer, T1N0M0. She underwent a left modified radical mastectomy and immediate breast reconstruction with the placement of an Inamed (formerly McGhan Medical Corporation, Santa Barbara, CA) Biocell tissue expander. The tissue expander was replaced at 3 months with an Inamed Biocell Style 363 textured saline breast implant. She did well until 1996 when she developed cellulitis of the left upper extremity associated with chronic lymphedema. In 2000 she underwent an implant replacement for a size change due to weight gain, and her implant was replaced with a second Inamed Biocell textured saline implant. In 2008 the patient presented with a deflation of her saline implant and the implant was replaced with an Allergan (Allergan, Inc., Irvine, CA) Natrelle Style 410 highly cohesive textured silicone gel implant. In December of 2015, seven years after her last revision, the patient developed a large seroma and discomfort. She underwent ultrasound-guided aspiration of her fluid collection and 60 cc of turbid fluid was removed and sent for routine cultures, Gram stain, and cytology. An additional sample of fluid and peripheral blood was collected and sent for clinical study, which was approved by the Institutional Review Board at Roger Williams Medical Center. Informed consent was obtained from the patient for the collection of seroma, blood, and tissue samples. Routine aerobic and anaerobic cultures revealed no bacterial growth and local cytology revealed partially degenerated lymphocytes with proteinaceous debris and macrophages in the background. No epithelial cells were identified. In January 2016 the patient underwent explantation of her breast implant, a complete capsulectomy, and replacement to an Allergan Natrelle Inspira smooth round silicone gel implant. Periprosthetic fluid, capsular tissue, and peripheral blood were collected at the time of surgery and again submitted to the local pathology laboratory as well as for clinical study. Routine cultures were negative, and the capsule tissue pathology revealed fibro-collagenous and adipose tissue with synovial metaplasia consistent with capsule. The patient was seen at 6 months and one-year follow-up. The reconstructed breast has remained soft and stable. No further treatment or work-up is currently planned or indicated for this patient. For analysis of T lymphocytes in blood, 100 uL of whole blood was dispersed to each of 12 tubes, labeled with test antibodies, and analyzed in the same manner as described above for seroma fluid cells.
METHODS

RESULTS
Pathology
Cytospins revealed a spectrum of lymphoid cells including mature and transformed lymphocytes with deeply basophilic cytoplasm. Larger cells with vacuolated cytoplasm, and occasional lobulated nuclei and prominent nucleoli were noted; these latter cells were suspicious for ALCL (Figure 2 ). Only few mitoses were found. Occasional eosinophils, neutrophils, and macrophages were seen. Immunostaining of cytospins showed that >90% lymphocytes expressed pan T-cell antigen CD3 (not shown). 
Flow Cytometry
DISCUSSION
The mechanism by which ALCL develops around breast implants remains unknown. Chronic inflammation is known to be a precursor of many malignancies. We hypothesize that ALCL develops as a result of a sustained T-cell immune response to antigen(s), likely bacterial antigens, on breast implants. This is consistent with the reported direct linear correlation of CD4+ T cells and bacterial count in capsules involved by BIA-ALCL. 4 Our hypothesis is further supported here by detection of a nonmalignant CD30+ expanded T-cell population arising in a background of polyclonal T cells in a late seroma surrounding a breast implant. A cartoon illustrating restricted TCRVβ diversity in response to antigenic selection is shown in Figure 5 . The negative bacterial culture is not surprising because routine cultures are almost always negative due to the difficulty of culturing bacteria/biofilm. 7 Our finding is clinically significant for showing that CD30+ expression is not diagnostic of malignancy in delayed seromas around breast implants. The demonstration of an expanded CD30+ TCRVβ 13.2+ T-cell population in a polyclonal background suggests a possible role for bacterial superantigens as a pathogenic factor. Superantigens provide the only known mechanism for a polyclonal Vβ restricted expansion of T cells. 8 Superantigens can trigger a chronic immune response that provides the context for an aberrant T-cell clone, as demonstrated in the evolution of CD30+ large primary cutaneous T-cell lymphoma. 9 Superantigens are well known in Staphylococcal infections. TCRVβ13.2 has specificity for multiple Staphylococcal superantigens including staphylococcal enterotoxin B, 10 staphlococcal enterotoxin C1, 10, 11 and staphylococcal enterotoxin G. 10, 12 Superantigens are less well known in gram-negative bacterium but have been described for Yersinia pseudotuberculosis and Pseudomonas fluorescens in Crohn's disease. 13, 14 The bacterium associated with development of BIA-ALCL is a gram-negative bacillus Ralstonia spp, particularly Ralstonia pickettii, reported in nosocomial infections from contamination of solutions (eg, water for injections, aqueous chlorhexidine solution) and has been recently reported as an uncommon cause of infection associated with catheters and elbow arthroplasty. 4 No superantigens have yet been discovered to be produced by Ralstonia, but our case should stimulate this line of investigation. 
CONCLUSION
The findings of this study, if confirmed in additional cases currently under investigation, suggest that BIA-ALCL may be the end stage of a CD30+ T-cell lymphoproliferative disorder. One of us (MEK) has reported molecular evidence of a clonal relationship between early regressing skin lesions of lymphomatoid papulosis (LyP) and subsequent cutaneous ALCL. 15, 16 The median time of clinically detected ALCL from onset of LyP skin lesions or breast implant is 8 to 10 years, the clinical course of both cutaneous ALCL and BIA-ALCL is typically indolent, lymph node involvement infrequent and regional, and spontaneous regression frequently occurs. 17 Indeed, Brody et al have reported that the clinical course of ALCL in women with breast implants has "varied widely from a single positive cytology result followed by apparent spontaneous resolution, to disseminated treatment-resistant tumor and death." 18 Our finding of an expanded population of TCRVβ 13.2+ T cells in the blood is unexpected since the patient had no evidence of systemic disease (eg, autoimmune disorder). Scientific analysis of the explanted capsular tissue is currently being performed to investigate if bacteria or biofilm were present at the time of explantation. If our findings are reproducible in other patients, they may shed light on the pathogenesis of BIA-ALCL and stimulate further investigation of immune responses to antigens on breast implants.
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